Lifeline Biotechnologies (LLBO) Financial Statements

35 Followers

Lifeline Biotechnologies Financial Overview

Lifeline Biotechnologies's market cap is currently $3.48M. The company's EPS TTM is $; its P/E ratio is -103.16; Lifeline Biotechnologies is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 18	Dec 17
Income Statement
Total Revenue	$ 0.00	$ 350.00K
Gross Profit	$ 0.00	$ 349.37K
Operating Income	$ -43.39K	$ 241.91K
EBITDA	$ -43.39K	$ 242.54K
Net Income	$ -43.39K	$ 241.91K
Balance Sheet
Cash & Short-Term Investments	$ 415.00	$ 345.00
Total Assets	$ 440.99K	$ 503.37K
Total Debt	$ 327.12K	$ 383.50K
Net Debt	$ 326.70K	$ 383.16K
Total Liabilities	$ 385.79K	$ 404.78K
Stockholders' Equity	$ 55.20K	$ 98.59K
Cash Flow
Free Cash Flow	$ 139.82K	$ 45.22K
Operating Cash Flow	$ 139.82K	$ 45.22K
Investing Cash Flow	$ -83.37K	$ 0.00
Financing Cash Flow	$ -56.38K	$ -49.71K

Currency in USD

Lifeline Biotechnologies Earnings and Revenue History

Income Statement >

Lifeline Biotechnologies Debt to Assets

Balance Sheet >

Lifeline Biotechnologies Cash Flow

Cash Flow >

Lifeline Biotechnologies Forecast EPS vs Actual EPS

Currently, no data available

Please return soon. This page is being updated.

Earnings >